At the time of her first vedolizumab dose, she was hypoalbuminemic with serum albumin of 1.5, a known correlate for inferior serum levels of monoclonal antibodies, most commonly TNF-α inhibitors, used in the treatment of IBD [25]. This evidence concerns the gene TNF and inflammatory bowel disease.